Boston Scientific Q2 2026 Earnings Analysis
Impossibile aggiungere al carrello
Puoi avere soltanto 50 titoli nel carrello per il checkout.
Riprova più tardi
Riprova più tardi
Rimozione dalla Lista desideri non riuscita.
Riprova più tardi
Non è stato possibile aggiungere il titolo alla Libreria
Per favore riprova
Non è stato possibile seguire il Podcast
Per favore riprova
Esecuzione del comando Non seguire più non riuscita
Boston Scientific Q2 2026 Earnings Analysis
-
Letto da:
-
Di:
Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're diving into Boston Scientific's second quarter 2026 results — and Jordan, this one's got some real drama in it.
JORDAN: It really does. Before we jump in, quick disclaimer for everyone listening: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
ALEX: Right, so let's set the scene. Boston Scientific actually beat expectations in Q2 — organic sales grew 7%, ahead of their 5-7% guide, and adjusted EPS came in at 86 cents, up 15% year-over-year and above the high end of guidance.
JORDAN: On paper, that sounds like a great quarter. But here's the twist — right after touting the beat, management turned around and cut full-year guidance. Full-year organic revenue guidance moved down to 5-6%, and full-year EPS guidance came in at $3.28 to $3.32.
ALEX: And the culprit? Two of their hottest businesses over the last couple years — WATCHMAN and electrophysiology, or EP.
JORDAN: Let's start with WATCHMAN, the left atrial appendage closure device. This is a fascinating case of clinical evidence essentially colliding with commercial momentum. New studies — OCEAN, CHAMPION-AF — have been published over the past several months, and they're changing how doctors think about referring patients for the procedure.
ALEX: CEO Mike Mahoney was pretty candid about it. He said the U.S. market has "slowed sharply and unexpectedly." Standalone WATCHMAN procedures — meaning not done alongside another heart procedure — are actually declining in the low teens percentage-wise.
JORDAN: The one bright spot is "concomitant" procedures — done at the same time as another cardiac procedure — which grew over 60%. But even that's expected to slow in the second half because of tougher comparisons.
ALEX: So full-year WATCHMAN growth guidance is now flat to low single digits, with the second half actually expected to decline mid-to-high single digits. That's a big swing from where this business has been.
JORDAN: Then there's EP, the electrophysiology business built around their FARAPULSE technology — that's the pulsed field ablation, or PFA, platform for treating atrial fibrillation. Management admitted they simply underestimated competitive pressure in the U.S.
ALEX: Which is almost ironic, because Boston Scientific basically created this PFA market boom. Mahoney noted PFA now makes up something like 80% of the U.S. AFib ablation market — a shift that happened faster than anyone expected, and that success invited competitors in quicker than the company modeled.
JORDAN: Meanwhile, international EP growth is still humming along around 20%. It's really a U.S.-specific share story, not a "the technology doesn't work" story.
ALEX: Here's something I found reassuring, though. Management pointed out that roughly 75% of Boston Scientific's revenue — everything outside WATCHMAN and EP — is still expected to grow about 6% in the second half, which is right in line with their historical trend.
JORDAN: Right, and there were genuinely strong pockets. Neuromodulation grew 12%. Interventional cardiology grew 15%. Interventional oncology grew 12%. This isn't a company falling apart — it's two specific franchises hitting an air pocket.
ALEX: Let's talk strategy, because they also announced a restructuring program targeting about $500 million in run-rate savings by the end of 2029, with more than half of that realized by exiting 2027.
JORDAN: That's a real signal — they're bracing for a tougher stretch and want to fund future growth catalysts without blowing up margins. CFO Jon Monson said savings will show up first in SG&A, then in cost of goods sold over time.
ALEX: And on th
This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione